INTRODUCTION
During the differentiation of B-lineage lymphocytes, recombinations in the variability (V), diversity (D) and junction (J) segments occur in the heavy-chain immunoglobulin (IgH) gene, resulting in relatively conserved regions (frameworks) and hypervariable regions (complementarity determining regions, CDRs). One of these hypervariable regions, CDR-3, is unique in each B-cell lineage. [1] [2] [3] These sequences can be amplified by polymerase chain reaction using consensus primers for the conserved regions that flank the CDR-3 of IgH [4] [5] [6] [7] and can be used as clonal markers of B-lineage acute lymphocytic leukemia in minimal residual disease studies. 3, [8] [9] [10] [11] [12] [13] [14] [15] [16] The presence of oligoclonal populations in B-lineage acute lymphoblastic leukemia has been detected in a variable number of cases in studies by Southern blot and polymerase chain reaction and may be associated with a poorer prognosis for the disease. [17] [18] [19] Furthermore, the presence of more than one clone detected at diagnosis may strongly interfere with the detection of minimal residual disease. [20] [21] [22] [23] In the present study we correlated the presence of bi/oligoclonality, detected by polymerase chain reaction in Brazilian children with B-lineage acute lymphoblastic leukemia, with immunophenotype, risk group and disease-free survival.
METHODS

Patients
Sixty pediatric patients with B-lineage acute lymphoblastic leukemia were admitted for treatment to the Pediatric Clinic of the University Hospital, Faculty of Medicine of Ribeirão Preto, University of São Paulo, from December 1990 to September 1996. Forty-seven of these children were eligible for the study, 11 were excluded due to lack of stored DNA at diagnosis or lack of polymerase chain reaction amplification, and 2 were lost to follow-up. The diagnosis was based on morphological analysis according to the criteria proposed by the French-AmericanBritish cooperative group, 24 and on immunophenotyping by flow cytometry with monoclonal antibodies. The patients were classified and treated according the Brazilian Childhood Leukemia Treatment Group (GBTLI) protocols. 25 The 47 patients studied (14 girls and 33 boys) ranged in age from 7 months to 13 years (mean: 5.3 years). Complete remission was considered to have occurred when morphological analysis showed less than 5% blasts in bone marrow, and was obtained within 45-117 months (median: 83 months). The patients were investigated in terms of immunophenotyping, risk group and event-free survival.
Of the 47 patients studied, 38 were classified as common leukemia (CALLA+), five as early pre-B (CALLA-), one as B (slg+), one as biphenotypic (lymphoid/myeloid), one as B-lineage lymphoid blast transformation (CALLA-) involving a patient with chronic myelogenous leukemia, and in one it was not possible to perform immunotyping, although amplification for IgH was obtained by
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• Carlos Alberto Scrideli La Jolla, CA, USA). Care was taken to reduce the risk of sample contamination. 28 A positive and negative control was used for each reaction and all samples were analyzed at least twice.
A 10-15 µl amount of the product amplified by polymerase chain reaction in 5 µl ficoll/bromophenol blue buffer was submitted to 15% polyacrylamide gel electrophoresis (1-8 V/cm), stained with ethidium bromide (1 µg/ml), visualized in a ultraviolet transilluminator and photographed. 27 A marker with fragments of known size was used for comparison with the samples during electrophoresis. The clonality of B-lineage lymphocytes was characterized by the presence of one fragment (monoclonal) or 2 or more fragments (bi/ oligoclonal) of homogeneous size from 80 to 120 pb 4, 5, 10 ( Figure 1 ). Data were analyzed statistically by the exact Fisher test for mean comparison, and disease-free survival was analyzed by Kaplan-Meyer survival analysis and by the log-rank test, 29 with a cut-off date in July 2000. The disease-free survival of each child was analyzed, with the event being time of relapse or death. Patients who died without reaching remission were counted as having the event during month zero. The calculations were made using the GraphPad Prism software (San Diego, CA, USA). Table 2 .
RESULTS
Bi
Of the 15 patients with bi/oligoclonality, 7 were submitted to karyotyping analysis. Changes were found in 5 cases: 2 with changes of the chromosome 14, with trisomy in one of them and structural alteration [t(2;14)(p12;q31)] in the other; and 3 patients presented monosomy of sex chromosomes (2 in the X chromosome and one in the Y).
Of the 32 patients with monoclonality, 13 were submitted to karyotyping analysis. Structural changes were the most frequent alterations, consisting of 5 translocations [1 t(2;17)(p22;q25), 1 t(8;14)(q24;q31), 2 t(4;11)(q21;q25) and 1 (9;22)(q32;q11)] and one deletion [del 16(q22)]. All of these patients suffered relapses or died. Near triploid/hyperdiploidy was observed in 2 patients who were in remission (Table 1) .
There was no significant difference between groups in terms of relapse (p: 1.000), risk group (p: 1.000) or presence of CALLA (p: 1.000) when the data were analyzed by the exact Fisher test. Disease-free survival was also similar for both groups (p: 0.7695), with no significant difference by the log-rank survival method (Table 2 and Figure 2 ). The complete continuous remission times for the groups were similar, 47-117 months (median: 96) for the bi/oligoclonal group and 45-116 months (median: 83) for the monoclonal group.
Appropriate leukemia classification is essential for improving therapeutic approaches. Several factors have been clearly associated with higher chances of relapse, while others are currently under investigation. Age, white blood cell count at diagnosis, immunophenotyping, DNA index, cytoreduction time, central nervous system involvement and specific chromosomal abnormalities have been shown to be useful polymerase chain reaction. Twenty-nine children were considered to be at high risk for relapse and 18 were considered to be at standard risk, in accordance with the Brazilian Childhood Leukemia Treatment Group criteria. 25 Karyotype obtained by bone marrow aspirates was analyzed by G-banding techniques, according to ISCN criteria. Some of these patients were reported in a previous study.
7
Sample Preparation and Polymerase Chain Reaction
Bone marrow samples were obtained by aspiratory puncture at diagnosis and analyzed by polymerase chain reaction in accordance with Saiki et al. 26 DNA was extracted by digestion with proteinase K, extraction with phenol/chloroform/isoamyl alcohol, precipitation with sodium acetate and ethanol, and quantification by spectrophotometry at 260 and 280 nm absorbance. 27 Genomic DNA (0.1-0.2 µg) was added to 23 µl of reaction solution containing 2 mM of each dNTP, 2.5 µl reaction buffer (Gibco BRL, Gaithersburg, MD, USA), 1.5 mM MgCl 2 , 1 U taq polymerase, 0.5 to 1 µl FR3A primer (sense), LJH or VLJH (antisense), 5 and 20 µl mineral oil. After an initial denaturation at 94 ºC for 5 minutes and annealing at 57 ºC for 2 minutes, each sample was submitted to 35 cycles with extension at 72 ºC, denaturation at 94 ºC and annealing at 54 ºC for 1 minute 20 seconds each, with final extension at 72 ºC for 10 minutes in a RoboCycler 40 thermocycler (Stratagene, as prognostic factors and have been used for classifying childhood acute lymphoblastic leukemia in risk groups, with differentiated treatment protocols for each group. 25 Some studies [17] [18] [19] have associated the presence of oligoclonality in childhood Blineage acute lymphoblastic leukemia with an adverse clinical outcome, which could have a use as a prognostic factor. This association, however, has not detected by others. 20, 35, 36, 42, 43 In the present study, when patients with bi/oligoclonality and monoclonality were compared in terms of relapse, presence of CALLA and risk group, no statistically significant differences were detected. Analysis of disease-free survival has also shown no difference between the two groups up to the present time and, in our patients, this does not suggest that bi/ oligoclonality was associated with worse clinical outcome.
Despite improvements in leukemia treatment, 20-30% of children still relapse. 12, 17 The study of minimal residual disease for follow-up and early detection of relapses using consensus primers for CDR-3 has been used by several authors for establishing prognosis in such patients. 8, 9, 11, 12, 39, 40 The presence of bi/ oligoclonality at diagnosis, as well as clonal evolution during the course of the disease, may be a problem in the detection and study of minimal residual disease using primers or probes for rearranged VH-D-JH. This is due to the possibility that smaller clones present at diagnosis may emerge as major clones in acute lymphoblastic leukemia patients who suffer a relapse. 20, 21, 34 It has been suggested that the instability of IgH rearrangements increases as a function of time. 33, 38 The presence of bi/ oligoclonality or clonal evolution, although relatively frequent, is mostly associated with the same D-JH sequence, with events in the rearranged VH gene being more common (VH to VH, VH to D-JH). 30, 33, 37, 38, 41 Bi/oligoclonality in a rearranged IgH gene has been detected in 20 to 50% of B-lineage acute lymphoblastic leukemia cases in studies by Southern blot 17, 18, [30] [31] [32] and in 10-40% of cases by polymerase chain reaction. 20, 31, 33, 34 The explanation for the difference in oligoclonality findings may be due to the fact that incomplete D-J rearrangements can be detected by southern blot but not by polymerase chain reaction. The latter is normally based on the use of primers for the V region that may not be present in such rearrangements. 31, 33 In the present study, bi/ oligoclonality was detected by polymerase chain reaction in 31.9% of cases.
Some mechanisms have been proposed for explaining the presence of bi/ oligoclonality in B-lineage acute lymphoblastic leukemia. The IgH gene located on chromosome 14q32.2 31 may be amplified in the presence of chromosome 14 polysomy. Kitchingman et al. 18 detected hyperdiploidy in 9/18 pediatric patients with oligoclonality, and 8 of them presented polysomy of chromosome 14. Forestier et al., 35 Moreira et al. 36 and Schardt et al., 30 in studies on children and adults, respectively, found no alterations of chromosome 14. In the present study, the karyotype was analyzed in 7/15 cases with bi/oligoclonality, and changes in chromosome 14 were detected in 2 cases, one of them with polysomy and the other with structural alterations, i.e. t(2;14)(p12;q31). These data suggest that other mechanisms in addition to polysomy of chromosome 14 may be involved.
Another explanation for bi/oligoclonality may be the presence of two different cell populations in bone marrow, either due to two separate events or, more commonly, to the formation of subclones. Four different mechanisms have been proposed thus far for the formation of subclones: VH-VH substitution, VH rearrangement in a preexisting D-JH segment, substitution in the rearranged D-JH gene, or ongoing rearrangements in a non-rearranged precursor cell. 32, 37, 38 Some authors [17] [18] [19] suggest that these clones might be associated with unfavorable clinical outcome, because they could be responsible for disease progression, through selection of those with higher proliferation rate and acquired drug resistance. This study and others 20, 35, 36, 42, 43 are in disagreement with that hypothesis, since there was no association between the presence of oligoclonality and adverse clinical outcome.
CONCLUSION
The presence of bi/oligoclonality was not associated with a greater chance of relapse, immunophenotyping or risk group, and that its detection in 31.9% of the patients may be important for the study and followup of minimal residual disease. 
